[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-439718-105":59,"doc-detail-439718-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-reported-outcomes-of-a-randomized-phase-iii-clinical-trial-of-adjuvant-radiation-versus-chemoradiation-in-intermediate-risk-stage-iiia-cervical-cancer-patients-treated-with-initial-radical-hysterectomy-and-pelvic-lymphadenectomy-nrggog-0263","Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)","","Randomized phase III clinical trial results focus on patient-reported outcomes comparing adjuvant radiation versus chemoradiation in intermediate-risk stage I/IIA cervical cancer patients. Participants received initial radical hysterectomy and pelvic lymphadenectomy as baseline treatment. The publication reports bibliographic details for a 2025 Gynecologic Oncology article and identifies the trial as NRG/GOG-0263. It also includes statements on open-access licensing under CC BY and documents authorship, competing interest disclosures, and author contribution roles.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-reported-outcomes-of-a-randomized-phase-iii-clinical-trial-of-adjuvant-radiation-versus-chemoradiation-in-intermediate-risk-stage-iiia-cervical-cancer-patients-treated-with-initial-radical-hysterectomy-and-pelvic-lymphadenectomy-nrggog-0263/439718/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-reported-outcomes-of-a-randomized-phase-iii-clinical-trial-of-adjuvant-radiation-versus-chemoradiation-in-intermediate-risk-stage-iiia-cervical-cancer-patients-treated-with-initial-radical-hysterectomy-and-pelvic-lymphadenectomy-nrggog-0263/439718.png","ImageObject",300,407,{"name":92,"@type":93},"Terk","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the randomized phase III trial compare in intermediate-risk cervical cancer patients?","Question",{"text":112,"@type":113},"It compares adjuvant radiation versus chemoradiation for intermediate-risk stage I/IIA cervical cancer patients after initial radical hysterectomy and pelvic lymphadenectomy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the trial identifier for this study?",{"text":117,"@type":113},"The trial is identified as NRG/GOG-0263.",{"name":119,"@type":110,"acceptedAnswer":120},"Is the article open access, and under what license?",{"text":121,"@type":113},"Yes. The article is open access under the CC BY license.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},439718,1790965920,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1099525198933,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Gynecol Oncol. Author manuscript; available in PMC 2026 January 05. |\n| --- | --- |\n\nPublished in final edited form as:  \nGynecol Oncol. 2025 November ; 202: 102–109. doi:10.1016/j.ygyno.2025.09.014 .  \nPatient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)  \nDana M. Chasea,* , Helen Q. Huangb, Wei Dengb, Wui-Jin Kohc, William Rodgersd, William Small Jre, Kevin Albuquerquef, Jyoti Mayadevg, Charles A. Leathh, Bradley Monki,1 , BeobJong Kimj, Dae-Yeon Kimk, Chi Heum Chol, Jae-Weon Kimm, Jae Hong Non, Laura Holmano, Ashley Stuckeyp, Denise Fabianq, Alexandra H. Smicka, Lari Wenzelr, Karen Gils, Sang Young Ryut  \nThis is an open access article under the CC BY license ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)).  \n*Corresponding author at: Division of Gynecologic Oncology, 100 Medical Plaza Ste 383, Los Angeles, CA 90095, United States of A1m*DricaBr.admcdleyhaMse@monk isednecurr.ucntllay .eatduFlo(Drid.Ma .ChaseCancer)S. pecialists and Research Institute; West Palm Beach, FL 33401  \nDeclaration of competing interest  \nDr. Dana Chase received all support for the present manuscript, as well as grants/contracts from NRG Oncology. She also received consultant/speaker fees from Pfizer and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Pfizer.  \nDr. William Small Jr. received consulting fees from GlaxoSmithKline for consultation on KMB21 data in endometrial cancer (August– September 2024) and consultation on Optimal Management of Endometrial Cancer in the Evolving Treatment Landscape (June 2025–May2026). He also received payment for honoraria for invited talks from Zeiss. He received support for attending meetingsand/or travel from ACR and NRG Oncology. He participated on a Data Safety Monitoring Board, Glioblastoma from Novocure. He was on the Board of Chancellors, Chair Radiation Oncology Commission from ACR; was Treasurer/President-Elect for ARS; on the Board of Directors for TARGIT Collaborative Group; was President for the Illinois Radiological Society and was Director, Cardinal, Bernardin Cancer Center, Chair, Radiation Oncology at Loyola University Chicago.  \nDr., Jyoti Mayadev received consulting fees from AstraZeneca, Merck and Varian, as well as payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. She also received support for attending meetings and/or travel from NRG Oncology and Merck. She participated on Advisory Boards for Merck and Varian. She served on the Board of Directors for ABS and GOG Foundation.  \nDr. Charles A. Leath III’s institution received NIH Grants – NIH UG1233330 and P50 CA098252. His institution provided Contracted Research from Agenus and Seattle Genetics. He received payment for Lecture Honorarium from Merck. He also received travel support for attending meetings from Merck. He participated in the Scientific Advisory Boards for Merck and Seattle Genetics.  \nDr. Ashley Stuckey received royalties or licenses as an UptoDate reviewer.  \nDr. Denise Fabian is on the NRG Oncology Cervix Committee member.  \nAll other co-authors have no conflicts of interest to declare.  \nCRediT authorship contribution statement  \nDana M. Chase: Writing – review & editing, Writing – original draft, Methodology, Investigation, Formal analysis, Conceptualization. Helen Q. Huang: Writing – review & editing, Formal analysis. Wei Deng: Writing – review & editing. Wui-Jin Koh: Writing – review & editing, Conceptualization. William Rodgers: Writing – review & editing, Writing – original draft, Supervision, Resources, Methodology, Conceptualizatio","cbCaitp7NJECSWGA","https://ap.wps.com/l/cbCaitp7NJECSWGA","pdf",778968,"English","# Publication information\n## Article citation and DOI\n## Trial description (NRG/GOG-0263)\n# Licensing\n# Competing interest declaration\n# CRediT authorship contributions","[{\"question\":\"What does the randomized phase III trial compare in intermediate-risk cervical cancer patients?\",\"answer\":\"It compares adjuvant radiation versus chemoradiation for intermediate-risk stage I/IIA cervical cancer patients after initial radical hysterectomy and pelvic lymphadenectomy.\"},{\"question\":\"What is the trial identifier for this study?\",\"answer\":\"The trial is identified as NRG/GOG-0263.\"},{\"question\":\"Is the article open access, and under what license?\",\"answer\":\"Yes. The article is open access under the CC BY license.\"}]","Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263) | PDF",1790690003,48]